ArticlePharmaceutics2024

In Vivo Predictive Dissolution and Biopharmaceutic-Based In Silico Model to Explain Bioequivalence Results of Valsartan, a Biopharmaceutics Classification System Class IV Drug.

Isabel Gonzalez-Alvarez et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.